A Randomized, Double Blind, Placebo-Controlled, Multicenter Phase II Trial of Allisartan Isoproxil in Essential Hypertensive Population at Low-Medium Risk
Fig 3
The dynamic changes of clinical DBP and SBP in patient.
DBP(A) and SBP(B) at baseline and week 2,4,8 after treatment with Allisartan Isoproxil 240mg and placebo were recorded. The changes of DBP (C) and SBP (D) at week 2,4,8 after treatment with Allisartan Isoproxil 240mg and placebo compareing to baseline were showed. Data are given as mean ±SD.*P<0.05, **P<0.01 compared with the placebo group.